| Weight | 0,05 kg |
|---|
Eloralintide 10mg
Research Grade Peptide
- Research Grade
- 99% Purity
- Third-Party Verified
Reference Strength: 10mg
R2399,00
CAS: 2883634-40-8
Formula: C201H319N49O65S2
Molecular Weight: 4526.10 g/mol
Chemical Name / Amino Acid Sequence: {γGlu}-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gly-{Orn}-Leu-Ala-Glu-{(α-Me-Phe)}-Leu-Val-Arg-Ser-Ser-Asn-{(N-Me-Asn)}-Phe-Gly-Pro-{Lys(γGlu-γGlu-C20 diacid)}-Leu-Pro-Pro-Thr-Glu-Val-Gly-Ser-Asn-Thr-Tyr-NH2
Availability: In stock
SKU: ELO10
R2399,00
AVAILABLE FROM WEDNESDAY, 9TH OF SEPTEMBER 2026
Eloralintide (LY3841136) is an investigational, long-acting and selective amylin receptor agonist being developed for obesity and metabolic research. Human Phase 1 research has evaluated once-weekly subcutaneous administration and demonstrated dose-related pharmacokinetic exposure together with clinically meaningful reductions in body weight at higher studied doses.
Availability: In stock
Included with your purchase
Each qualifying product includes 3ml of 0.9% Benzyl Alcohol Bacteriostatic Water.
Complimentary Purchase Kit
Every qualifying vial includes a complimentary purchase kit at no additional cost.
Research Overview
About Eloralintide 10mg
Eloralintide is a modified peptide designed to reproduce selected biological actions of amylin while preferentially activating the amylin 1 receptor (AMY1R). Amylin is involved in appetite, satiety and regulation of food intake. Unlike GLP-1 receptor agonists, eloralintide acts primarily through the amylin-receptor system, making it an important emerging research approach for body-weight management.
How It Works in Research
Eloralintide is an engineered amylin analogue designed for prolonged biological activity. It selectively activates amylin receptors, with laboratory characterization showing preferential activity at human AMY1R compared with AMY3R and the calcitonin receptor. Amylin signalling participates in the physiological regulation of satiety and meal size. By engaging this system, eloralintide is being investigated for its ability to reduce appetite and food intake and thereby influence body weight. Preclinical studies demonstrated dose-dependent reductions in food intake and body weight, with weight reduction occurring primarily through loss of fat mass. Translational research also suggested less conditioned taste avoidance than cagrilintide in a rat model, although animal tolerability findings cannot be assumed to predict comparative human tolerability. Human Phase 1 multiple-dose research subsequently evaluated eloralintide once weekly for 12 weeks in participants with obesity or overweight. Pharmacokinetic exposure increased approximately proportionally with dose, supporting its development as a long-acting weekly research compound.
Research Applications
Appetite and satiety signalling • Food-intake regulation • Body-weight reduction • Fat-mass reduction • Obesity and overweight • Amylin-receptor pharmacology • Metabolic research • Combination approaches with incretin-based therapies
Eloralintide is a long-acting peptide being studied for appetite and weight regulation. It targets the amylin-receptor system, which helps communicate fullness and regulate food intake. Its long duration of action has enabled once-weekly subcutaneous administration in human clinical research.
So someone may simply feel satisfied with less food rather than needing as much food to feel finished.
Retatrutide = appetite + glucose/nutrient signalling + energy metabolism
Eloralintide = a more targeted satiety/fullness signal to the brain
Product Specifications
- Product Name: Eloralintide
- Research Code: LY3841136 / LY-3841136
- CAS Number: 2883634-40-8
- Molecular Formula: C201H319N49O65S2
- Molecular Weight: 4526.10 g/mol
- Reference Strength: 10 mg
- Appearance: White to off-white solid
Research Information
- Category: Long-acting selective amylin receptor agonist
- Primary Research Area: Obesity, appetite, satiety and metabolic research
- Clinical Research Route: Subcutaneous
- Clinical Research Frequency: Once weekly in published multiple-dose Phase 1 research
- Dry Storage Reference: −20 °C approximately 1 year; −80 °C approximately 2 years
Mechanism of Action
Eloralintide is an engineered amylin analogue designed for prolonged biological activity. It selectively activates amylin receptors, with laboratory characterization showing preferential activity at human AMY1R compared with AMY3R and the calcitonin receptor. Amylin signalling participates in the physiological regulation of satiety and meal size. By engaging this system, eloralintide is being investigated for its ability to reduce appetite and food intake and thereby influence body weight.
Key Research Characteristics
Investigational long-acting peptide • Research code: LY3841136 / LY-3841136 • Selective amylin receptor agonist • Preferential activity at human AMY1R • Once-weekly subcutaneous administration studied in humans • Clinical research focus: obesity and overweight • Distinct mechanism from GLP-1 receptor agonists
Potential Benefits in Research
Reduced appetite and food intake observed in preclinical research.
Dose-dependent reductions in body weight and fat mass were observed in animal models.
Human Phase 1 research demonstrated body-weight reduction during once-weekly treatment at studied doses.
Long-acting pharmacokinetics support once-weekly clinical investigation.
Its selective amylin-receptor profile provides a mechanistically distinct research pathway from GLP-1 receptor agonism.
Safety Profile
In the published 12-week Phase 1 multiple-dose study, commonly reported treatment-emergent events included decreased appetite, headache and fatigue.
Gastrointestinal and tolerability effects remain important areas of investigation for amylin-based therapies.
Research Applications
Appetite and satiety signalling • Food-intake regulation • Body-weight reduction • Fat-mass reduction • Obesity and overweight • Amylin-receptor pharmacology • Metabolic research • Combination approaches with incretin-based therapies
REFERENCE RECONSTITUTION INFORMATION
Research Goal: Investigate selective amylin-receptor activation in appetite, food-intake, body-weight and metabolic models. Evidence Status: Preclinical studies plus published Phase 1 human studies; ongoing clinical development. Human Clinical Route: Subcutaneous injection. Human Clinical Frequency: Once weekly in the published multiple-dose Phase 1 study. Published Human Dose Exposure: Single-dose Phase 1 research evaluated 0.04–12 mg. Product Strength: 10 mg vial.
Always follow sterile preparation techniques when handling research peptides.
The Pure Performance Labs profile records the published clinical-research doses and frequency without converting them into a self-administration titration schedule.
General Preparation
Published Phase 1 multiple-dose research evaluated 1.2 mg, 3 mg, 6 mg and 12 mg administered subcutaneously once weekly for 12 weeks without dose escalation.
Eloralintide (10mg) - RECONSTITUTION TABLES
Reference Handling Information
Reference information for laboratory handling of Eloralintide 10mg.
- Subcutaneous injection once weekly in published multiple-dose Phase 1 research.
Reference Parameters (Published Clinical Research Summary (weekly subcutaneous injection))
| Dosage | Dose | Reconstituted with 2ml | Units |
|---|---|---|---|
| Low | 2.5 mg | 50 | |
| Medium | 5 mg | 100 | |
| Higher | 7.5 mg | 2 x 75 | |
| Highest Phase 1 repeated dose | 10 mg | 2 x 100 |
For laboratory research only.
Experimental Study Period
STUDY PERIOD
12 weeks
ADJUSTMENT NOTES
Without dose escalation
RESEARCH CONTEXT
Investigate selective amylin-receptor activation in appetite, food-intake, body-weight and metabolic models.
Once weekly in the published multiple-dose Phase 1 study.
Research-supplier reference information for eloralintide lists sealed storage protected from moisture.
Dry material is listed for storage at −20 °C for approximately 1 year or −80 °C for approximately 2 years.
Prepared laboratory stock solutions are listed for frozen storage, with avoidance of repeated freeze–thaw cycles.
These are research-material storage references. Storage for a specific Pure Performance Labs batch should follow its batch-specific COA and validated stability information.
View Certificate of Analysis
View Certificate of Analysis Each batch of Eloralintide is independently tested by third-party laboratories. Download the Certificate of Analysis to verify purity, identity, and quality.
99%
Verified Purity
3rd Party
Lab Tested
Certified
Quality Assured
Only logged in customers who have purchased this product may leave a review.
Related products
-
Metabolic Research
Tesamorelin
Price range: R750,00 through R1599,00 Select options This product has multiple variants. The options may be chosen on the product page -
Metabolic Research
Tirzepatide
Price range: R799,00 through R1699,00 Select options This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.
Only logged in customers who have purchased this product may leave a review.
PURE PERFORMANCE LABS
Recommended Research Products
Explore related compounds commonly viewed alongside this product.
FOR RESEARCH PURPOSES ONLY
This product is intended for research and laboratory use only. Always consult qualified researchers and follow appropriate safety protocols.
Reviews
There are no reviews yet.